The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billi... ( BURLINGTON Mass. Sept. 21 /- Decision...)

HOME >> MEDICINE >> TECHNOLOGY

The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billion in 2019

Date:9/21/2010

BURLINGTON, Mass., Sept. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of key agents such as Merck's Januvia, Eli Lilly/Amylin/Alkermes' Bydureon and Amylin/Eli Lilly's Byetta will drive the type 2 diabetes drug market to nearly double from $19 billion in 2009 to $36 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Type 2 Diabetes reveal that agents from the incretin mimetics drug class—dipeptidyl peptidase-IV (DPP-IV) inhibitors and glucagon-like peptide-1 (GLP-1) analogues—are the most promising drug classes because they improve upon key areas of safety and efficacy. DPP-IV inhibitors such as Januvia have a very low risk of hypoglycemia and an excellent tolerability profile, making them suitable for widespread use. GLP-1 analogues such as Bydureon and Byetta combine superior glucose-lowering and weight-loss capabilities and are particularly useful for the significant proportion of type 2 diabetics who are obese. Among all drug classes, DPP-IV inhibitors and GLP-1 analogues will experience the largest upturn in market share, increasing from 12 percent in 2009 to 30 percent in 2019.

"Januvia dominates the DPP-IV inhibitor class and will consolidate its leading position while other DPP-IV inhibitors will struggle, owing to their lack of clinical advantages over Januvia," said Decision Resources Analyst Yannick Maneuf, Ph.D. "GLP-1 analogues have a strong efficacy profile, they elicit weight loss and also have limited safety liabilities and—despite requiring an injection—GLP-1 analogues enjoy great popularity among thought leaders, who see improved glycemia and weight loss in obese type 2 diabetics as landmark progress."

Bydureon, a once-weekly therapy, will earn the most sales in the GLP-1 analo
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. K-V Pharmaceutical Company Receives Notification From New York Stock Exchange of Compliance With Quantitative Continued Listing Standards
2. Interventional Spine®, Inc. Announces Continued Success With Its Unique PERPOS® Percutaneous Cervical System
3. K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards
4. Caraco Pharmaceutical Laboratories, Ltd. Receives Notice Regarding NYSE Amex Continued Listing Standards
5. Department of Defense Funding Shows Continued and Bi-Partisan Support for STB® Lifesaving Technologies Products to Stop Blood Loss
6. Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year
7. Abbott Annual Meeting Highlights Continued Strong Performance in 2009; Sustained Growth in 2010
8. Philips Introduces Breakthrough Medical Alert Service That Helps Enable Continued Independence for Seniors by Improving Access to Help in the Event of a Fall
9. NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards
10. Benefits of CyberKnife Radiosurgery for Lung Cancer Drive Continued Adoption
11. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C

Post Your Comments:

(Date:5/17/2013)... May 17, 2013 Boehringer Ingelheim will contribute ... at the American Thoracic Society International Conference (ATS ... May 17 – 22. Data will ... the treatment of chronic obstructive pulmonary disease (COPD) ... as investigational compounds for asthma, idiopathic pulmonary fibrosis ...

(Date:5/17/2013)... , May 17, 2013 Oramed ... of oral drug delivery systems, announced today that the ... the Company,s Investigational New Drug application(IND) for ORMD-0801, its ... to have the FDA clearance to proceed," stated ... upcoming trial is a major milestone for Oramed and ...

(Date:5/16/2013)... MECHELEN, Belgium , May 17, 2013 ... ABBV ) announced today an extension of ... Galapagos will fund and complete a Phase 2 program ... progression into Phase 3. Upon successful completion of the ... $50 million. The terms of the collaboration extension are ...

Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8 Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2 Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3 AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2 AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3 AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4 AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5 AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6

[0] Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference [0] Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.[0] AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease

... Inc. (Nasdaq: IPCM ), a leading national hospitalist physician group practice company, announced ... Wednesday, November 11, 2009 at the 2009 Annual Credit Suisse Health Care Conference in ... Event: 2009 Annual Credit ... Date: Wednesday, November ...

... SAN FRANCISCO, Nov. 4 VIA Pharmaceuticals, Inc. (Nasdaq: ... development of compounds for the treatment of cardiovascular and ... Vice President Research & Development will present "VIA-3196, a ... the Abstract Oral Session on Novel Biological Mechanisms of ...

Cached Medicine Technology:IPC The Hospitalist Company, Inc. to Present at the 2009 Annual Credit Suisse Health Care Conference 2 VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 2 VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 3 VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 4

IPC The Hospitalist Company, Inc. to Present at the 2009 Annual Credit Suisse Health Care Conference VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009

(Date:5/20/2013)... May 20, 2013 AURORA, Colo. – ... online accredited university, has developed a Bachelor of ... assess how they feel about continuing their education and ... print out the complimentary worksheet, respond to ten statements ... they rate on a BSN-readiness scale. , New industry ...

(Date:5/20/2013)... (PRWEB) May 20, 2013 Can you tell a ... to tell a joke? , Would you like to be funnier ... sometimes feel like your funny bone is missing? , Can't think ... 2 hours later? , If this sounds like you, don't worry. ... and develop their sense of humor; and even learn to tell ...

(Date:5/20/2013)... 2013 The transvaginal mesh lawyers at ... firm, report that two important bellwether trials are set ... and federal litigations established for C.R. Bard transvaginal ... C.R. Bard bellwether trial will begin in the federal ... Virginia. (In re: C.R. Bard, Inc., Pelvic Repair ...

(Date:5/20/2013)... May 20, 2013 Townsend Security, ... announced that the company’s Alliance Key Manager hardware ... with Key Connection for TrueCrypt for Windows ... strong passwords when using TrueCrypt for data protection. ... offer secure password management for TrueCrypt encryption. Today's ...

(Date:5/20/2013)... May 20, 2013 Gerald Wojtala, executive ... will speak at North Carolina Food Safety and Defense ... Business: The Need for Partnerships – from Farm to ... conference, scheduled for May 22-23 at the Sheraton Imperial ... the food sector have in protecting the food supply. ...

Breaking Medicine News(10 mins):Health News:American Sentinel University Develops New Worksheet to Help Nurses Determine BSN-Readiness 2 Health News:American Sentinel University Develops New Worksheet to Help Nurses Determine BSN-Readiness 3 Health News:Psychologist Steve Wilson Gives A Dozen Tips to Help You Be More Humorous Even if You Can't Tell a Joke 2 Health News:Psychologist Steve Wilson Gives A Dozen Tips to Help You Be More Humorous Even if You Can't Tell a Joke 3 Health News:Psychologist Steve Wilson Gives A Dozen Tips to Help You Be More Humorous Even if You Can't Tell a Joke 4 Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 2 Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 3 Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 4 Health News:Alliance Key Manager, Townsend Security’s FIPS 140-2 Compliant Encryption Key Manager Now Includes Support for Managing TrueCrypt Passwords 2 Health News:Alliance Key Manager, Townsend Security’s FIPS 140-2 Compliant Encryption Key Manager Now Includes Support for Managing TrueCrypt Passwords 3 Health News:IFPTI Executive Director to Speak at North Carolina Food Safety and Defense Task Force Annual Conference 2

[0] American Sentinel University Develops New Worksheet to Help Nurses Determine BSN-Readiness [0] Psychologist Steve Wilson Gives A Dozen Tips to Help You Be More Humorous Even if You Can't Tell a Joke [0] Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials [0] Alliance Key Manager, Townsend Security’s FIPS 140-2 Compliant Encryption Key Manager Now Includes Support for Managing TrueCrypt Passwords [0] IFPTI Executive Director to Speak at North Carolina Food Safety and Defense Task Force Annual Conference

... (ESMO) just released an enhanced and revised set ... the best quality care to their patients. ... vital, evidence-based information including the incidence of the ... assessment, treatment plans and follow-up. Formerly known ...

... precancers and cervical cancers is over 50 per cent more ... study in Mexico has revealed. Results of the largest ... a Latin American country point to the readiness of HPV ... online today (8 July 2010) in Cancer, Causes and ...

... ... Attract Most Eyeballs in June , ... Vancouver, BC, Canada (PRWEB) -- Suite101.com, a global content site that provides trusted and ... its site in June 2010, providing a window into consumer online reading behavior. In June, ...

... HealthDay Reporter , WEDNESDAY, July 7 (HealthDay News) ... may be able to control it more effectively on ... researchers contend. Through telemonitoring of their blood pressure ... in advance, patients assigned to self-managed care saw greater ...

... ... over the globe with their unbeatable embroidery and screen printing deals. New office space ... ... 2010 -- Uncle Sam can’t hold down this online apparel giant. Times may be ...

... , ... last week, funded by grants from the Mesothelioma Applied Research Foundation and the National ... in treatment and prevention of this aggressive and deadly cancer. , ... (PRWEB) July 8, 2010 -- Last ...

Cached Medicine News:Health News:ESMO publishes updated guidelines on cancer care 2 Health News:ESMO publishes updated guidelines on cancer care 3 Health News:HPV DNA testing over 50 percent more sensitive than cytology testing 2 Health News:Suite 101.com Provides Insight Into Consumer Reading Behavior Online 2 Health News:Suite 101.com Provides Insight Into Consumer Reading Behavior Online 3 Health News:Suite 101.com Provides Insight Into Consumer Reading Behavior Online 4 Health News:Monitoring Blood Pressure at Home May Help Keep It Low 2 Health News:Monitoring Blood Pressure at Home May Help Keep It Low 3 Health News:Clothing4all WOWs Yet Again With Customer Appreciation and Increased Sales 2 Health News:Discovery Opens Door for New Options in Prevention and Treatment of Mesothelioma 2 Health News:Discovery Opens Door for New Options in Prevention and Treatment of Mesothelioma 3

ESMO publishes updated guidelines on cancer care HPV DNA testing over 50 percent more sensitive than cytology testing Suite 101.com Provides Insight Into Consumer Reading Behavior Online Monitoring Blood Pressure at Home May Help Keep It Low Clothing4all WOWs Yet Again With Customer Appreciation and Increased Sales Discovery Opens Door for New Options in Prevention and Treatment of Mesothelioma

... with self-adjusting adaptability to fit almost every ... of angling at the sit of fixation ... permits it to be titled to any ... Intern®, a simple adjustment of the 3/D ...

Stainless steel construction to withstand sterilization modalities (EtO, Steris, and Sterrad)...

Inquire...

ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....

Medicine Products:

3D/SwingerOperating Table Clamp MicroLaparoscopes Ackerman Laparoscopes 10mm ENDOlap™ Millennium Laparoscopes